deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03782064

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

Sponsor: Beth Israel Deaconess Medical Center

Conditions Multiple Myeloma
Interventions DC/myeloma fusions/GM-CSF Nivolumab
Updated 11 times since 2019 Last updated: Jun 16, 2023 Started: Feb 22, 2019 Primary completion: Jan 31, 2021 Completion: Jan 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding

Other terminated trials from Beth Israel Deaconess Medical Center

See all terminations from Beth Israel Deaconess Medical Center

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

This PHASE2 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Beth Israel Deaconess Medical Center leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2019 – ~Jul 2019 · 6 months · monthly snapshotNot Yet Recruiting~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshotRecruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotRecruiting~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshotActive Not Recruiting~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshotTerminated~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshotTerminated~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshotTerminated~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Nov 2022 — Jul 2023 [monthly]

    Terminated PHASE2

  5. Sep 2022 — Nov 2022 [monthly]

    Terminated PHASE2

▶ Show 6 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jan 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Bristol-Myers Squibb
  • Dana-Farber Cancer Institute
Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations